glp 1 in heart failure Mechanisms of GLP-1 Receptor Agonists HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit SGLTi and GLP-1 in HF

The current regulatory environment is influenced by a September 2025 executive order aimed at enhancing transparency in DTC prescription drug advertising

When you increase your dose, the effective concentration in your body is not simply the new dose amount

Al completar la instalacin, inicia sesin con tus credenciales o crea una cuenta nueva

The team at Novo were confident that the Wegovy pill would be approved

If hed been asked that question 8 months ago, he would have waited 3, 4, 5, 6 or months to see if other treatments worked

With new guidance released by the Centers for Medicare & Medicaid Services, the episode explains how two upcoming federal programsthe Bridge Program (2026) and the Balance Model (2027)could expand access to medications like Zepbound and Wegovy